Global Transcriptional Changes Following Statin Treatment in Breast Cancer

  title={Global Transcriptional Changes Following Statin Treatment in Breast Cancer},
  author={{\'O}l{\"o}f Bjarnad{\'o}ttir and Siker Kimbung and Ida Johansson and Srinivas Veerla and Mats J{\"o}nsson and P{\"a}r-Ola Bendahl and Dorthe Aamand Grabau and Ingrid Hedenfalk and Signe Borgquist},
  journal={Clinical Cancer Research},
  pages={3402 - 3411}
Background: Statins purportedly exert antitumoral effects, but the underlying mechanisms are currently not fully elucidated. The aim of this study was to explore potential statin-induced effects on global gene expression profiles in primary breast cancer. Experimental Design: This window-of-opportunity phase II trial enrolled 50 newly diagnosed breast cancer patients prescribed atorvastatin (80 mg/day) for 2 weeks presurgically. Pre- and posttreatment tumor samples were analyzed using… 

High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer

Dysregulation of cholesterol biosynthesis is predictive for both sensitivity to anti-cancer statin therapy and prognosis following primary breast cancer diagnosis.

Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency

This study indicates that simvastatin potentially affects the activity of transcriptional factors such as ets-1 and dusp4 through the MAPK pathway and statins might be potential candidates for TNBC therapy reducing eTS-1 expression via overexpression of dUSP4.

Atorvastatin Inhibits Breast Cancer Cells by Downregulating PTEN/AKT Pathway via Promoting Ras Homolog Family Member B (RhoB)

The exact mechanism of ATO's carcinostatic effects in breast cancer is related to downregulating PTEN/AKT pathway via promoting RhoB, and this study demonstrates the potential applicability of R HoB as a therapeutic target for breast cancer.

Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway

In ER-positive and ER-negative breast cancer cells, simvastatin treatment consistently induced apoptosis and inhibited proliferation by deregulating caspase cascades and cell cycle proteins in a dose dependent manner and were reversed by metabolic products of the mevalonate pathway.

The effect of statin treatment on intratumoral cholesterol levels and LDL receptor expression: a window-of-opportunity breast cancer trial

An upregulation of LDLR and preserved intratumoral cholesterol levels in breast cancer patients treated with statins are shown, suggesting a potential role for LDLR in the statin-induced regulation of breast cancer cell proliferation.

RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype

The nuclear receptor RORγ is identified as a novel master regulator of cholesterol metabolism in triple negative breast cancer (TNBC) and small-molecule antagonists induce tumor regression in patient-derived xenografts and immunocompetent mouse models.

Evaluation of anti-proliferative activity of simvastatin and atorvastatin on MCF7 cell line compared with doxorubicin using MTT test

SimVastatin and atorvastatin had anti-proliferative effect on MCF7 cell line and displayed significant synergism with doxorubicin which will help in enhancing efficacy of doxorbicin and decrease the adverse effect.

Elevated expression of A-Raf and FA2H in hepatocellular carcinoma is associated with lipid metabolism dysregulation and cancer progression.

The study suggests that FA2H and A-Raf play major role in HCC progression, and has identified a novel HCC-specific network among these proteins and their interactors representing a complex inter-relationship between signaling pathways that may regulate HCC development.

Statins: a role in breast cancer therapy?

Ongoing translational clinical trials aimed at biomarker discovery will help identify, which breast cancer patients are most likely to benefit from adjuvant statin therapy, and will add valuable clinical knowledge to the field.



Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial

It is suggested that HMGCR is targeted by statins in breast cancer cells in vivo, and that statins may have an anti-proliferative effect in H MGCR-positive tumors.

Practical implications of gene-expression-based assays for breast oncologists

The clinical utility of gene-expression-based assays and their technical potential as clinical tools vis-a-vis the performance of breast cancer biomarkers that are the current standard of care are discussed.

Breast cancer growth prevention by statins.

In vivo results showed that oral dosing of statins significantly inhibited the growth of a mouse mammary carcinoma, and supporting rationale for future statin trials in breast cancer patients is provided.

Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells

Several candidate predictors of sensitivity to fluvastatin treatment in breast cancer, which warrant further preclinical and clinical evaluation, are identified.

Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer

Fuvastatin showed measurable biologic changes by reducing tumor proliferation and increasing apoptotic activity in high-grade, stage 0/1 breast cancer and support further evaluation of statins as chemoprevention for ER-negative high grade breast cancers.

Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation

Details of pathways interacting with intense GNRHR signaling are revealed, a dynamic response to the GNRH superagonist Triptorelin is demonstrated, and the NF-κB survival pathway is implicates as a node for enhancing GNRH agonist-induced anti-proliferation.

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

The presence of tumor-associated lymphocytes in breast cancer is a new independent predictor of response to anthracycline/taxane neoadjuvant chemotherapy and provides useful information for oncologists to identify a subgroup of patients with a high benefit from this type of chemotherapy.

Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study.

The results suggest that cerivastatin inhibits cell signaling pathways involved in the invasiveness and metastatic properties of highly invasive cancers.